The biomarker clinical phase outsourcing services global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Biomarker Clinical Phase Outsourcing Services Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The biomarker clinical phase outsourcing services market size has grown exponentially in recent years. It will grow from $7.91 billion in 2023 to $9.71 billion in 2024 at a compound annual growth rate (CAGR) of 22.7%. The growth in the historic period can be attributed to rising government initiatives and funding, increasing diagnostic applications of biomarkers, a rise in R&D funding from the government, rapid advancements in technologies such as genomics, proteomics, and imaging, and the increasing demand for cancer biomarkers.
The biomarker clinical phase outsourcing services market size is expected to see exponential growth in the next few years. It will grow to $22.09 billion in 2028 at a compound annual growth rate (CAGR) of 22.8%. The growth in the forecast period can be attributed to the increasing use of biomarkers in the various phases of clinical trials. The use of biomarkers in clinical trials continues to expand, as does the growing demand for precision medicines, the rising adoption of companion diagnostics, and the and the increasing demand for personalized medicine. Major trends in the forecast period include advanced parameters in the trials, diagnostic-focused clinical phases, rapid advancements in biomarker technology, rising government initiatives and funding, and advancements in technology.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report
Scope Of Biomarker Clinical Phase Outsourcing Services MarketThe Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Biomarker Clinical Phase Outsourcing Services Market Overview
Market Drivers –
The rise in clinical trials is expected to propel the growth of the biomarker clinical phase outsourcing services market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. The surge in clinical trials is facilitated by advancements in medical research, rising prevalence of chronic diseases, increased funding from both governmental and private sources, and the growing demand for innovative treatments and therapies. Outsourcing providers often have specialized knowledge and experience in biomarker discovery, validation, and analysis. This expertise can enhance the quality and reliability of the biomarker data collected during the trial. For instance, in May 2023, according to the United States National Library of Medicine, registered clinical trials increased from 399,499 in 2022 to 437,533 in all 50 states and across 221 countries. Furthermore, it was reported that 140,492 studies (31%) are registered in the United States only, whereas 241,498 studies (53%) are recorded in non-U.S. locations. Therefore, the rise in clinical trials will drive the growth in the biomarker clinical phase outsourcing services market forward.
Market Trends –
Major companies in the biomarker clinical phase outsourcing services are focusing on advancements with high-throughput flow cytometry and ELISpot testing to gain a competitive edge in the market. High-throughput flow cytometry and ELISpot testing are utilized for biomarker analysis, offering rapid and precise assessment of immune responses and cellular markers. For instance, in November 2022, Celerion Inc., a US-based biotechnology outsourcing services company, expanded its service offering to include GLP/GCP-compliant molecular and cell biology testing. This strategic move aims to enhance Celerion’s capabilities in supporting clients throughout the drug development process, from early clinical research to regulatory submissions. Celerion can provide a more comprehensive range of services by adding GLP/GCP-compliant molecular and cell biology tests, such as pharmacokinetic (PK), pharmacodynamic (PD), and biomarker analysis. This expansion enables Celerion to assist clients in producing high-quality data that meets regulatory requirements, thereby speeding up the development of new medicines.
The biomarker clinical phase outsourcing services market covered in this report is segmented –
1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types
2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis
3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutions
Get an inside scoop of the biomarker clinical phase outsourcing services market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp
Regional Insights –
North America was the largest region in the biomarker clinical phase outsourcing services market in 2023. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies –
Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Intertek Group plc, Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Bioclinica Inc., Evotec SE, GenScript Biotech Corporation, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Selvita S.A., BioIVT LLC, Discovery Life Sciences LLC, Metabolon Inc., Caprion Proteomics Inc., Canopy Biosciences LLC
Table of Contents
1. Executive Summary2. Biomarker Clinical Phase Outsourcing Services Market Report Structure3. Biomarker Clinical Phase Outsourcing Services Market Trends And Strategies4. Biomarker Clinical Phase Outsourcing Services Market – Macro Economic Scenario5. Biomarker Clinical Phase Outsourcing Services Market Size And Growth…..27. Biomarker Clinical Phase Outsourcing Services Market Competitor Landscape And Company Profiles28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
